Expanded Access Policy

MapLight Therapeutics is a clinical-stage biopharmaceutical company working to develop targeted, novel therapeutics to improve the lives of people with brain disorders.

Our rigorous clinical trials are designed, conducted, and monitored to enable MapLight and regulatory agencies to evaluate the safety and efficacy of investigational therapies before they are more broadly available to patients, and we believe that participation in these trials represents the safest way for patients to gain access to these compounds. Therefore, at this time, enrollment in clinical trials is the only way for patients to access MapLight’s investigational therapies.

You and your health care provider can find additional information about MapLight’s ongoing clinical trials by accessing https://clinicaltrials.gov.

As more data on the safety and efficacy of investigational therapies becomes available, MapLight will review and may revise this Expanded Access Policy at any time, as authorized by the 21st Century Cures Act. The posting of this policy by MapLight shall not serve as a guarantee of access to any specific investigational medicine by any individual patient. 

If you have additional questions, please speak with your treating physician, or contact MapLight at info@maplightrx.com